Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 301–400 of 963
Eviz, E., Kıllı, N. E., Karakus, K. E., Can, E., Gökçe, T., Mutlu, G. Y., & Hatun, Ş. (2024) · Diabetic Medicine · doi:10.1111/dme.15333 · Cited by 24
Kellett, J. E., Sampson, M., Swords, F. M., Murphy, H. R., Clark, A., Howe, A. C., Price, C., Datta, V., & Myint, K. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13656 · Cited by 28
Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality
Wei, Y., Andersson, T., Tuomi, T., Nyström, T., & Carlsson, S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf304 · Cited by 25
Kieć‐Wilk, B., Matejko, B., Raźny, U., Stankiewicz, M. A., SKUPIEN, J. K., Klupa, T., & Malecki, M. T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.002 · Cited by 22
Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset
Edqvist, J., Rawshani, A., Rawshani, A., Adiels, M., Franzén, S., Bjorck, L. M., Svensson, J., Lind, M., Sattar, N. A., & Rosengren, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002187 · Cited by 25
Self-citationSherr, J. L., Bergford, S., Gal, R. L., Clements, M. A., Patton, S. R., Calhoun, P. M., Beaulieu, L. C., & Riddell, M. C. (2024) · Diabetes Care · doi:10.2337/dc23-2212 · Cited by 23
Self-citationGłowińska‐Olszewska, B., Borysewicz-Sańczyk, H., Sawicka, B., Klonowska, B., Charemska, D., Żelazowska‐Rutkowska, B., & Bossowski, A. T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00431 · Cited by 25
“The risk of atherosclerosis development and early ischemic heart disease in T1DM patients is several times higher than in the general population (3).”
BackgroundCaracterísticas clínicas y manejo de la diabetes tipo 1 en España. Estudio SED1
Peralta, F. G., Torre, E. L. M., Conde, S., Conget, I., & Novials, A. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.11.002 · Cited by 33
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 22
van Raalte, D. H., & Bjornstad, P. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz228 · Cited by 24
Liu, S., Leone, M., Ludvigsson, J. F., Lichtenstein, P., D'Onofrio, B. M., Svensson, A., Guðbjörnsdóttir, S., Bergen, S. E., Larsson, H., Kuja‐Halkola, R., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1347 · Cited by 28
Self-citationSchiaffini, R., Lumaca, A., Martino, M., Rapini, N., Deodati, A., Amodeo, M. E., Ciampalini, P., Matteoli, M. C., Pampanini, V., & Cianfarani, S. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3826 · Cited by 23
Using Large Diabetes Databases for Research
Wild, S. H., Fischbacher, C., & McKnight, J. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816645120 · Cited by 23
Macedoni, M., Hovnik, T., Plesnik, E., Kotnik, P., Bratina, N., Battelino, T., & Grošelj, U. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.013 · Cited by 22
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not
Beck, R. W. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0602 · Cited by 23
Mallone, R., Bismuth, É., Thivolet, C. H., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., & Beltrand, J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101603 · Cited by 23
Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy
Brugnara, L., Mallol, R., Ribalta, J., Vinaixa, M., Murillo, S., Casserras, T., Guardiola, M., Vallvé, J.-C., Kalko, S. G., Correig, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136348 · Cited by 25
Farahna, M., Etet, P. F. S., Osman, S. Y., Yurt, K. K., Amir, N., Vecchio, L., Aydin, I., Aldebasi, Y. H., Sheikh, A., Chijuka, J. C., et al. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.11.001 · Cited by 20
Type 1 diabetes during adolescence: International comparison between Germany, Austria, and Sweden
Hanberger, L., Samuelsson, U., Holl, R. W., Fröhlich-Reiterer, E. E., Åkesson, K., & Hofer, S. E. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12591 · Cited by 22
Tsur, A., Cahn, A., Israel, M., Feldhamer, I., Hammerman, A., & Pollack, R. M. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3355 · Cited by 24
“T1D remains associated with increased mortality relative to the age and sex-matched general population.(3-5) Maintaining glycemic control with intensive insulin therapy has been shown to prevent microvascular and macrovascular complications and reduce the risk of increased mortality.”
BackgroundLudvigsson, J., Routray, I., Vigård, T., Hanås, R., Rathsman, B., Carlsson, A., Särnblad, S., Albin, A., Arvidsson, C., Samuelsson, U., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3440 · Cited by 21
Simon, A. B., Derella, C. C., Blackburn, M., Thomas, J., Layman, L. C., Nicholson, M. S., Waller, J. L., Elmarakby, A. A., Saad, K. M., & Harris, R. A. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01966-6 · Cited by 22
Elbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01184-w · Cited by 20
Campbell, M. D., Walker, M., Ajjan, R., Birch, K. M., Gonzalez, J. T., & West, D. J. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117698918 · Cited by 23
Jendle, J., Smith-Palmer, J., Delbaere, A., de Portu, S., Papo, N., Valentine, W., & Roze, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0294-z · Cited by 20
Age at type 1 diabetes onset: a new risk factor and call for focused treatment
Basina, M., & Maahs, D. M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31811-7 · Cited by 26
Zhao, L. P., Papadopoulos, G. K., Kwok, W. W., Moustakas, A. K., Bondinas, G. P., Larsson, H. E., Ludvigsson, J., Marcus, C., Samuelsson, U., Wang, R., et al. (2020) · Diabetes · doi:10.2337/db20-0075 · Cited by 23
Ibfelt, E. H., Wibæk, R., Vistisen, D., Andersen, G. S., Jørgensen, M. E., Hulmán, Á., Dabelea, D., Birkebæk, N., Svensson, J., & Rønn, P. F. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13337 · Cited by 20
Admission glucose as a prognostic marker for all-cause mortality and cardiovascular disease
Djupsjö, C., Kuhl, J., Andersson, T., Lundbäck, M., Holzmann, M. J., & Nyström, T. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01699-y · Cited by 24
Nielens, N., Pollé, O. G., Robert, A. R., & Lysy, P. A. (2018) · Journal of Diabetes Research · doi:10.1155/2018/5936360 · Cited by 22
Wolf, P. S., Fellinger, P., Pfleger, L., Smajis, S., Beiglböck, H., Gajdošík, M., Anderwald, C. H., Trattnig, S., Luger, A., Winhofer, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39362-4 · Cited by 22
Mortality in Type 1 Diabetes in the Current Era: Two Steps Forward, One Step Backward
Katz, M. L., & Laffel, L. M. (2015) · JAMA · doi:10.1001/jama.2014.16327 · Cited by 26
Eeg‐Olofsson, K., Nathanson, D., Spelman, T. D., Kyhlstedt, M., Bülow, E., Levrat‐Guillen, F., & Bolinder, J. (2024) · Diabetes Care · doi:10.2337/dc24-0690 · Cited by 25
Ducluzeau, P., Fauchier, G., Herbert, J., Semaan, C., Halimi, J., Angoulvant, D., & Fauchier, L. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101429 · Cited by 20
Dei, A., Aldigeri, R., Mantovani, A., Masulli, M., Palmisano, L., Cavalot, F. L., Bonomo, K., Baroni, M. G., Cossu, E., Cavallo, M. G., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad127 · Cited by 24
Isaksson, S. S., Imberg, H., Hirsch, I. B., Schwarcz, E., Hellman, J., Wijkman, M. O., Bolinder, J., Nyström, T., Holmer, H., Hallström, S., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06151-2 · Cited by 21
Self-citationCichosz, S. L., Olesen, S. S., & Jensen, M. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241286907 · Cited by 27
New Insights into Diabetes Cell Therapy
Lysy, P. A., Corritore, E., & Sokal, E. M. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0729-3 · Cited by 21
Ahlén, E., Pivodic, A., Wedel, H., Dahlqvist, S., Kosiborod, M., & Lind, M. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816652901 · Cited by 19
Self-citationSugiyama, T., Goryoda, S., Inoue, K., Ihana‐Sugiyama, N., & Nishi, N. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2784-0 · Cited by 19
Doubova, S. V., Ferreira‐Hermosillo, A., Pérez‐Cuevas, R., Barsoe, C., Gryzbowski-Gainza, E., & Valencia, J. E. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3412-3 · Cited by 23
“T1D patients face a two-fold risk of death from any cause in comparison to matched controls, and the risk increases with elevated levels of glycated hemoglobin (HbA1c) and is highest for patients with HbA1c > 9% [11].”
BackgroundYadegarfar, G., Anderson, S. G., Khawaja, Z., Cortés, G., Leivesley, K., Metters, A., Horne, L., Steele, T., & Heald, A. H. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000216 · Cited by 20
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
“This is associated with both acute and chronic complications; diabetic ketoacidosis (DKA) and hypoglycemia, and microangiopathic and macroangiopathic complications.(4,5) The Diabetes Control and Complications Trial (DCCT) data showed a 35% to 76% reduction in microvascular disease in the intensive treatment group (med…”
BackgroundSejling, A., Schouwenberg, B., Færch, L., Thorsteinsson, B., de Galan, B. E., & Pedersen‐Bjergaard, U. (2015) · Diabetic Medicine · doi:10.1111/dme.12810 · Cited by 24
The clinical potential of low-level C-peptide secretion
Ludvigsson, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1210513 · Cited by 20
Mertens, J., Weyler, J., Dirinck, E. L., Vonghia, L., Kwanten, W. J., Gaal, L. F. V., Winter, B. Y. D., Francque, S., & Block, C. E. M. D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02764-y · Cited by 23
Jeandidier, N., Chaillous, L., Franc, S., Benhamou, P., Schaepelynck, P., Hanaire, H. P., Catargi, B., Farret, A., Fontaine, P., Guerci, B., et al. (2018) · JMIR Research Protocols · doi:10.2196/resprot.9154 · Cited by 21
Auto-immunity and the gut microbiome in type 1 diabetes: Lessons from rodent and human studies
Snethlage, C. M. F., Nieuwdorp, M., van Raalte, D. H., Rampanelli, E., Verchere, C. B., & Hanssen, N. M. J. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101544 · Cited by 21
Welters, A., Tittel, S. R., Laubner, K., Laimer, M. W., Tschöpe, D., Mader, J. K., Merger, S. R., Milek, S., Kummer, S., & Holl, R. W. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108973 · Cited by 21
Riveline, J., Vergès, B. L., Detournay, B., Picard, S., Benhamou, P., Bismuth, É., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101306 · Cited by 20
Quinn, L. M., Shukla, D., Greenfield, S., Barrett, T. G., Garstang, J. J., Boardman, F., Litchfield, I. J., Dayan, C. M., Gardner, C., Connop, C., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002750 · Cited by 19
The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth
Pease, A., Callander, E. J., Zomer, E., Abraham, M. B., Davis, E. A., Jones, T. W., Liew, D., & Zoungas, S. (2022) · Diabetes Care · doi:10.2337/dc21-2019 · Cited by 19
Garofolo, M., Russo, E., Miccoli, R., Lucchesi, D., Giusti, L., Sancho‐Bornez, V., Daniele, G., Prato, S. D., & Penno, G. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.03.012 · Cited by 20
Fabris, C., Özaslan, B., & Breton, M. D. (2019) · Sensors · doi:10.3390/s19245386 · Cited by 21
“Despite the improving accuracy of BG monitoring devices [5,6] and the growing development of decision support systems [7,8], suboptimal insulin replacement remains common in T1D, leading to excess mortality and complication rates that are still significantly higher when compared to the general population [9,10].”
BackgroundFelix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 19
Casas, R., Dietrich, F., Puente-Marín, S., Barcenilla, H., Tavira, B., Wahlberg, J., Achenbach, P., & Ludvigsson, J. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01852-9 · Cited by 18
Lipes, M. A., & Galderisi, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0598-1 · Cited by 19
Melin, E. O., Dereke, J., & Hillman, M. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0268-0 · Cited by 22
“Women with T1D also have a significantly greater excess risk of death from cardiovascular (CV) disease across all age groups compared to men with T1D [4].”
BackgroundInfluentialAmsberg, S., Wijk, I., Livheim, F., Toft, E., Johansson, U.-B., & Anderbro, T. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022234 · Cited by 17
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.(44) The ACT intervention has potential to improve glycaemic control due to including seven sessions covering all six core ACT processes to train psychological flexibility.”
BackgroundCardiovascular Magnetic Resonance as Pathophysiologic Tool in Diabetes Mellitus
Mavrogeni, S. I., Bacopoulou, F., Markousis‐Mavrogenis, G., Giannakopoulou, A., Kariki, O. K., Vartela, V., Kolovou, G. D., Charmandari, E., & Chrousos, G. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672302 · Cited by 20
Fathi, A. E., Fabris, C., & Breton, M. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795895 · Cited by 19
“Nevertheless, T1D patients are still not achieving their glycemic targets (9), with complication rates and excess mortality significantly higher in T1D compared to the general population (10).”
BackgroundIndications for Insulin Pump Therapy in Type 1 Diabetes and Associations With Glycemic Control
Jendle, J. H., Rawshani, A., Svensson, A.-M., Avdic, T., & Gudbjörnsdóttir, S. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816650209 · Cited by 17
Cause-specific mortality in a cohort of Brazilian patients with type 1 diabetes
Gomes, M. B., Almeida, A. P. F., Santos, D. C., Silva, E. L. C., Cunha, E. F., & Negrato, C. A. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0975-0 · Cited by 18
Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes
Vestberg, D., Rosengren, A., Eeg‐Olofsson, K., Miftaraj, M., Franzén, S., Svensson, A., & Lind, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000727 · Cited by 18
Self-citationManagement of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes
Katz, M. L., Guo, Z., & Laffel, L. M. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.11.059 · Cited by 18
Sudhanshu, S., Nair, V., Godbole, T., Reddy, S. V. B., Bhatia, E., Dabadghao, P., Sharma, K., Arora, P., Bano, S., Singh, A., et al. (2019) · Indian Pediatrics · doi:10.1007/s13312-019-1497-3 · Cited by 19
A multiparameter model for non-invasive detection of hypoglycemia
Elvebakk, O., Tronstad, C., Birkeland, K. I., Jenssen, T. G., Bjørgaas, M. R., Gulseth, H. L., Kalvøy, H., Høgetveit, J. O., & Martinsen, Ø. G. (2019) · Physiological Measurement · doi:10.1088/1361-6579/ab3676 · Cited by 18
“Even with adequate monitoring and treatment, people with type 1 diabetes (T1D) have higher morbidity and mortality than the general population (Livingstone et al 2012, Secrest et al 2010, Lind et al 2014).”
BackgroundO’Reilly, J. E., Blackbourn, L. A. K., Caparrotta, T. M., Jeyam, A., Kennon, B., Leese, G., Lindsay, R. S., McCrimmon, R. J., McGurnaghan, S. J., McKeigue, P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05173-w · Cited by 22
Ambinathan, J. P. N., Sridhar, V. S., Lytvyn, Y., Lovblom, L. E., Liu, H., Bjornstad, P., Perkins, B. A., Lovshin, J. A., & Cherney, D. Z. I. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107880 · Cited by 21
Ståhl, C. H., Lind, M., Svensson, A. ‐., Kosiborod, M., Guðbjörnsdóttir, S., Pivodic, A., Clements, M. A., & Rosengren, A. (2017) · Diabetic Medicine · doi:10.1111/dme.13292 · Cited by 17
Self-citationThe influence of food order on postprandial glucose levels in children with type 1 diabetes
Faber, E. M., van Kampen, P. M., Boers, A. C.-D., Houdijk, E. C. A. M., & van der Kaay, D. C. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12640 · Cited by 20
Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
Nijhoff, M. F., & de Koning, E. J. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1073-6 · Cited by 20
Alhakak, A., Butt, J. H., Gerds, T. A., Fosbøl, E. L., Mogensen, U. M., Krøll, J., Pallisgaard, J. L., Gislason, G., Torp-Pedersen, C. T., Køber, L., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14604 · Cited by 15
Stephen, D. A., Nordin, A., Nilsson, J., & Persenius, M. W. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01039-x · Cited by 25
Epitope-based precision immunotherapy of Type 1 diabetes
Firdessa-Fite, R., Genzano, C. B., Mallone, R., & Creusot, R. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2154098 · Cited by 16
Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
Mohandas, D., Calma, J., Gao, C., & Basina, M. (2023) · Endocrines · doi:10.3390/endocrines4010008 · Cited by 19
Hero, C., Karlsson, S. A., Franzén, S., Svensson, A., Miftaraj, M., Guðbjörnsdóttir, S., Sundell, K. A., Eliasson, B., & Eeg‐Olofsson, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000719 · Cited by 17
Self-citationde Mattos, A. C. M. T., Campos, Y. S., Fiorini, V. O., Sab, Y., Tavares, B. L., Velarde, L. G. C., Lima, G. A. B., & Filho, R. A. D. C. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000228 · Cited by 21
Psychological Symptoms and Quality of Life After Simultaneous Kidney and Pancreas Transplantation
Nijhoff, M. F., Hovens, J. G. F. M., Huisman, S. D., Ringers, J., Rabelink, T. J., de Fijter, H. J. W., van der Boog, P. J. M., & de Koning, E. J. P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000996 · Cited by 18
“§ indicates Malignancy (1): nonmelanoma skin cancer.”
Case Fatality of Patients With Type 1 Diabetes After Myocardial Infarction
Kerola, A. M., Juonala, M., Palomäki, A., Semb, A. G., Rautava, P. T., & Kytö, V. (2022) · Diabetes Care · doi:10.2337/dc22-0042 · Cited by 17
Elevated risk of mortality in type 1 diabetes mellitus
Snell‐Bergeon, J. K., & Maahs, D. M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.245 · Cited by 18
Gaps in life expectancy for people with type 1 diabetes
Stene, L. C. (2016) · Diabetologia · doi:10.1007/s00125-016-3943-2 · Cited by 19
“Despite tremendous improvements in the prognosis for patients with type 1 diabetes since the 1920s, significant gaps in mortality compared with the general population remain [1–4].”
BackgroundMaffeis, C., Fornari, E., Morandi, A., Piona, C. A., Tomasselli, F., Tommasi, M., & Marigliano, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0993-y · Cited by 16
β-Cell Replacement Strategies: The Increasing Need for a “β-Cell Dogma”
Vieira, A., Druelle, N., Avolio, F., Napolitano, T., Sanz, S. N., Silvano, S., & Collombat, P. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00075 · Cited by 17
de Gonzalo‐Calvo, D., Colom, C., Viladés, D., Rivas-Urbina, A., Moustafa, A.-H., Pérez‐Cuellar, M., Sánchez‐Quesada, J. L., Pérez, A., & Llorente‐Cortés, V. (2018) · Scientific Reports · doi:10.1038/s41598-018-19230-3 · Cited by 18
Management of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Cardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Sharif, A., JENDLE, J. H., & Hellgren, K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00957-0 · Cited by 17
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 16
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
Henriksson, M., Jindal, R., Sternhufvud, C., Sörstadius, E., Bergenheim, K., & Willis, M. S. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2097 · Cited by 16
Amor, A. J., Ortega, E., Giménez, M., Cofán, M., Blanco, J., Pané, A., Boswell, L., Vinagre, I., Esmatjes, E., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.02.004 · Cited by 19
Ludvigsson, J., Routray, I., Elluru, S. R., Leanderson, P., Larsson, H. E., Rathsman, B., Hanås, R., Carlsson, A., Ek, T., Samuelsson, U., et al. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0078 · Cited by 14
Cano, A., Llauradó, G., Albert, L., Mazarico, I., Astiarraga, B., González-Sastre, M., Martínez, L., Fernández‐Veledo, S., Simó, R., Vendrell, J. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072192 · Cited by 15
Glycemic control and complications of type 1 diabetes among children in Tanzania
Najem, S., Majaliwa, E. S., Ramaiya, K. L., Swai, A. B. M., Jasem, D., & Ludvigsson, J. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100245 · Cited by 15
“However, in spite of modern treatment the mortality is still increased [5] and life expectancy is dramatically shorter than for individuals without T1D [6].”
BackgroundFaecal microbiota transplantation in endocrine diseases and obesity
Snethlage, C. M. F., Nieuwdorp, M., & Hanssen, N. M. J. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101483 · Cited by 20
Benefits and Hurdles of Pancreatic β-Cell Replacement
Bolla, A. M., Montefusco, L. B., Pastore, I., Lunati, M. E., Nasr, M. B., & Fiorina, P. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac058 · Cited by 19
Yokomichi, H., Nagai, A., Hirata, M., Kiyohara, Y., Muto, K., Ninomiya, T., Matsuda, K., Kamatani, Y., Tamakoshi, A., Kubo, M., et al. (2017) · Journal of Epidemiology · doi:10.1016/j.je.2016.12.013 · Cited by 16
Metabolic risk factors in adolescent girls with type 1 diabetes
Castro-Correia, C., Silva, R. S., Pinheiro, M. I., Costa, C., & Fontoura, M. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0053 · Cited by 18
Winocour, P. H., Bain, S. C., Chowdhury, T. A., De, P., Pokrajac, A., Fogarty, D. G., Frankel, A., Banerjee, D., Wahba, M. M., & Dasgupta, I. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.172 · Cited by 21
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.